Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
L. B. Cameron et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2022)
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
Tony Mok et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
Liang Zeng et al.
ONCOTARGETS AND THERAPY (2020)
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Igor Letovanec et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Gregory P. Kalemkerian et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
Trish Thorne-Nuzzo et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study
Elisa Gobbini et al.
LUNG CANCER (2017)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
ALK Protein Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
Antonio Marchetti et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2015)
Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
Fiona H. Blackhall et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Multicenter Immunohistochemical ALK-Testing of Non-Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria
Maximilian von Laffert et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A. T. Shaw et al.
ANNALS OF ONCOLOGY (2013)
Recommendations for the Analysis of ALK Gene Rearrangements in Non-Small-Cell Lung Cancer A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology
Antonio Marchetti et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
Erik Thunnissen et al.
VIRCHOWS ARCHIV (2012)
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung
Valentina Monica et al.
CLINICAL CANCER RESEARCH (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2009)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Share Paper
